Where Opportunity is Found - Research Report on Jazz Pharmaceuticals plc and Spectrum Pharmaceuticals, Inc.

 Where Opportunity is Found - Research Report on Jazz Pharmaceuticals plc and
                        Spectrum Pharmaceuticals, Inc.

As industry marked by roller coaster ups and downs, where does opportunity lie
ahead? Which companies have what it takes to survive regulatory approval and
oversight?

PR Newswire

NEW YORK, January 23, 2013

NEW YORK, January 23, 2013 /PRNewswire/ --

Biopharmaceutical companies Jazz Pharmaceuticals plc (NASDAQ: JAZZ) [Full
Research Report]^[1] and Spectrum Pharmaceuticals, Inc., (NASDAQ: SPPI) [Free
Research Report]^[^2^] have contrasting histories, but have the same positive
outlook for 2013. One has a history of massive returns in a short period of
time, making it one of the best investments in the market's most volatile
industry; and the other one had a rough 2012, but is expected to bounce back
and improve this year.

Jazz Pharmaceuticals is included in the expected great biotech stocks for
2013. The company's consensus price target is $69.18. If the target is right,
this implies almost 32 percent upside in 2013. What makes Jazz stand out is
its outperform rating and the expected sales gain of over 100 percent in 2012
is expected to show a 37 percent gain to $809 million in 2013. With earnings
expected to grow from about $4.73 per share in 2012 to $5.67 this year, shares
of Jazz Pharmaceuticals trade at less than 10 times the expected 2013
earnings.

Spectrum Pharmaceuticals, on the other hand, did not do well last year but
could see its fortunes change in the coming years. Solid results were reported
for its colorectal cancer drug, Fusilev. The announcement of its special
dividend allowed analysts and investors to see it sporting an attractive
valuation. Other good news for Spectrum Pharmaceuticals is that its CEO
recently announced that revenue for 2012 will be over $300 million, which
suggests strong Q4 sales, expecting growth in 2013. With a forward P/E ratio
of 8.08 and a price/sales under 3.0, Spectrum Pharmaceuticals can be
considered as a great long term investment.

The driving force behind the emerging biotech stocks is mergers and
acquisitions (M&A). M&A helps most biotech firms to fund research and
development (R&D) in order to discover and develop new and more advanced
generations of drugs. With a market cap of $3.27 billion, Jazz Pharmaceuticals
fits the M&A bill. For Spectrum Pharmaceuticals, as a small cap company, it is
critical for it to form partnerships with bigger companies to increase R&D
investments.

As a necessity, demand for drugs will always be high. Biotechnology is one of
the most volatile and unpredictable industries, with a high-risk, high-reward
scenario. Substantial gains have been seen in 2012, and 2013 seems more
promising for the industry.

Reference Links:

^[1]The Full Research Report on Jazz Pharmaceuticals plc - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.nationaltradersassociation.org/r/entire_report/e495_JAZZ]

^[^2^]The Free Research Report on Spectrum Pharmaceuticals, Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.nationaltradersassociation.org/r/entire_report/3dad_SPPI]

Consider National Traders Association

Tired of hearing about the latest, greatest trade opportunity... only to
realize that the ship has long sailed? You need a strong, informative
community in your arsenal. Join the group that has been consistently
identifying momentous situations as they develop -- long before they become
the next top news on major financial networks.

Contact: Demi Lapierre
Email: press@NationalTradersAssociation.org
Main: +1-(702)-212-4493

SOURCE National Traders Association